Immunoadjuvant Nanoparticles as Trojan Horses for Enhanced Photo-Immunotherapy in the Treatment of Triple-Negative Breast Cancer

被引:9
|
作者
Wu, Jinxian [1 ,2 ]
Wang, Shanyong [1 ,2 ]
Liu, Shanshan [1 ,2 ]
Liu, Fang [1 ,2 ]
Zhou, Feifan [1 ,2 ]
机构
[1] Hainan Univ, Sch Biomed Engn, Key Lab Biomed Engn Hainan Prov, Haikou, Peoples R China
[2] Hainan Univ, One Hlth Inst, Haikou, Peoples R China
基金
中国国家自然科学基金;
关键词
triple-negative breast cancer; nanoparticles; phototherapy; immunotherapy; metastasis; immune response;
D O I
10.3389/fphar.2022.883428
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment of triple-negative breast cancer (TNBC) faces great challenges due to high invasiveness and poor prognosis. Therefore, effective treatment methods are urgently needed to control primary tumors and suppress distant tumors. Herein, we employed glycated chitosan (GC), a polysaccharide macromolecular immunoadjuvant, to construct a self-assembly GC@ICG nanoparticle which is accessible to tumor cells for synergistic cancer treatment based on the combination of phototherapy and immunotherapy. In this strategy, the self-associated synthesis of spherical GC@ICG significantly improved the stability of ICG and endowed GC with Trojan Horses in tumor cells to enhance tumor immunogenicity. A bilateral 4T1 tumor-bearing mouse model was established to evaluate the therapeutic outcomes and specific host antitumor immune response. Finally, GC@ICG-based phototherapy can directly eliminate primary tumors and resist the progression of untreated distant tumors. In addition, compared to the treatment of L + GC + ICG, GC@ICG-based phototherapy was evidenced to suppress lung metastasis and enhance infiltration of CD8(+) T cells in untreated distant tumors. Therefore, this design shows promise in addressing the challenges of the treatment of TNBC.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Updates on the preoperative immunotherapy for triple-negative breast cancer
    Hu, Hong
    Kaklamani, Virginia
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [22] Progress and challenges of immunotherapy in triple-negative breast cancer
    Zhu, Yinxing
    Zhu, Xuedan
    Tang, Cuiju
    Guan, Xiaoxiang
    Zhang, Wenwen
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [23] Present and Future of Immunotherapy for Triple-Negative Breast Cancer
    Sriramulu, Sushmitha
    Thoidingjam, Shivani
    Speers, Corey
    Nyati, Shyam
    CANCERS, 2024, 16 (19)
  • [24] Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
    Luo, Chenyi
    Wang, Peipei
    He, Siqi
    Zhu, Jingjing
    Shi, Yuanyuan
    Wang, Jianxun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Immunotherapy in Triple-Negative Breast Cancer: Present and Future
    Isaac Kim
    Katherine Sanchez
    Heather L. McArthur
    David Page
    Current Breast Cancer Reports, 2019, 11 : 259 - 271
  • [26] Tumor microenvironment and immunotherapy for triple-negative breast cancer
    Guo, Zijie
    Zhu, Ziyu
    Lin, Xixi
    Wang, Shenkangle
    Wen, Yihong
    Wang, Linbo
    Zhi, Lili
    Zhou, Jichun
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [27] The clinical promise of immunotherapy in triple-negative breast cancer
    Vikas, Praveen
    Borcherding, Nicholas
    Zhang, Weizhou
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6823 - 6833
  • [28] Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer
    Llaguno-Munive, Monserrat
    Vazquez-Lopez, Maria Ines
    Garcia-Lopez, Patricia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [29] Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
    Bai, Xupeng
    Ni, Jie
    Beretov, Julia
    Graham, Peter
    Li, Yong
    JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (03): : 75 - 87
  • [30] Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
    Bezerra de Mello, Ramon Andrade
    Perez, Katia Roque
    Vazquez, Thais Perez
    IMMUNOTHERAPY, 2024, 16 (04) : 257 - 266